The researchers conducted a clinical trial, with grant support from St. Renatus, the product developer. In the study, 150 adults received either KOVANAZE or a placebo prior to undergoing a single dental filling in an upper bicuspid, canine or incisor.
Here’s what you need to know:
1. KOVANAZE was effective at preventing pain in 88 percent of patients. This rate is comparable to common injectable numbing agents.
2. The researchers found no serious side effects. The most common side effects included runny nose and nasal congestion.
3. Future research might investigate whether KOVANAZE can be used for more intensive dental procedures, like root canals or oral tissue biopsies.
More articles on anesthesia:
NorthStar Anesthesia implements EMR product Anesthesia Touch in 3 states: 3 notes
Anesthesia Business Consultants releases quarterly newsletter: 3 notes
Castle Connolly recognizes Dr. Semih Gungor as a top NY doctor: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.